A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Different Concentrations of QLM3004 in Delaying the Progression of Myopia in Children
Qilu Pharmaceutical Co., Ltd.
735 participants
Aug 20, 2023
INTERVENTIONAL
Conditions
Summary
Efficacy and Safety Study of QLM3004 in Myopic Children
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Low dose of QLM3004 Ophthalmic Solution 1 drop in each eye at bedtime
Medium dose of QLM3004 Ophthalmic Solution 1 drop in each eye at bedtime
High dose of QLM3004 Ophthalmic Solution 1 drop in each eye at bedtime
Vehicle
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06151587